Prior Infection and Passive Transfer of Neutralizing Antibody Prevent Replication of Severe Acute Respiratory Syndrome Coronavirus in the Respiratory Tract of Mice

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2004 Mar 16

PMID 15016880

Citations 284

Authors

Kanta Subbarao

Josephine McAuliffe

Leatrice Vogel

Gary Fahle

Steven Fischer

Kathleen Tatti

Michelle Packard

Wun-Ju Shieh

Sherif Zaki

Brian Murphy

Affiliations

Soon will be listed here.

Abstract

Following intranasal administration, the severe acute respiratory syndrome (SARS) coronavirus replicated to high titers in the respiratory tracts of BALB/c mice. Peak replication was seen in the absence of disease on day 1 or 2, depending on the dose administered, and the virus was cleared within a week. Viral antigen and nucleic acid were detected in bronchiolar epithelial cells during peak viral replication. Mice developed a neutralizing antibody response and were protected from reinfection 28 days following primary infection. Passive transfer of immune serum to naïve mice prevented virus replication in the lower respiratory tract following intranasal challenge. Thus, antibodies, acting alone, can prevent replication of the SARS coronavirus in the lung, a promising observation for the development of vaccines, immunotherapy, and immunoprophylaxis regimens.

Citing Articles

Animal Models for Human-Pathogenic Coronavirus and Animal Coronavirus Research.

Xiao F, Hu J, Xu M, Wang D, Shen X, Zhang H Viruses. 2025; 17(1).

PMID: 39861889 PMC: 11768759. DOI: 10.3390/v17010100.

Efficacy evaluation of a bivalent subunit vaccine against epidemic PEDV heterologous strains with low cross-protection.

Song X, Li Y, Wang C, Zhao Y, Yang S, Guo R J Virol. 2024; 98(10):e0130924.

PMID: 39254314 PMC: 11494954. DOI: 10.1128/jvi.01309-24.

Human coronavirus OC43 nanobody neutralizes virus and protects mice from infection.

Adair A, Tan L, Feng J, Girkin J, Bryant N, Wang M J Virol. 2024; 98(6):e0053124.

PMID: 38709106 PMC: 11237593. DOI: 10.1128/jvi.00531-24.

Ontology-based taxonomical analysis of experimentally verified natural and laboratory human coronavirus hosts and its implication for COVID-19 virus origination and transmission.

Wang Y, Ye M, Zhang F, Freeman Z, Yu H, Ye X PLoS One. 2024; 19(1):e0295541.

PMID: 38252647 PMC: 10802970. DOI: 10.1371/journal.pone.0295541.

Olfactory immunology: the missing piece in airway and CNS defence.

Wellford S, Moseman E Nat Rev Immunol. 2023; 24(6):381-398.

PMID: 38097777 PMC: 11560121. DOI: 10.1038/s41577-023-00972-9.

References

Renegar K . Influenza virus infections and immunity: a review of human and animal models. Lab Anim Sci. 1992; 42(3):222-32. View

Vennema H, de Groot R, Harbour D, Dalderup M, Gruffydd-Jones T, Horzinek M . Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization. J Virol. 1990; 64(3):1407-9. PMC: 249267. DOI: 10.1128/JVI.64.3.1407-1409.1990. View

Olsen C . A review of feline infectious peritonitis virus: molecular biology, immunopathogenesis, clinical aspects, and vaccination. Vet Microbiol. 1993; 36(1-2):1-37. PMC: 7117146. DOI: 10.1016/0378-1135(93)90126-r. View

Crowe Jr J, Bui P, London W, Davis A, HUNG P, Chanock R . Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis. Vaccine. 1994; 12(8):691-9. DOI: 10.1016/0264-410x(94)90218-6. View

Epstein S, Lo C, Misplon J, Lawson C, Hendrickson B, Max E . Mechanisms of heterosubtypic immunity to lethal influenza A virus infection in fully immunocompetent, T cell-depleted, beta2-microglobulin-deficient, and J chain-deficient mice. J Immunol. 1997; 158(3):1222-30. View

Burt F, Swanepoel R, Shieh W, Smith J, Leman P, Greer P . Immunohistochemical and in situ localization of Crimean-Congo hemorrhagic fever (CCHF) virus in human tissues and implications for CCHF pathogenesis. Arch Pathol Lab Med. 1997; 121(8):839-46. View

Vaughn D, Green S, Kalayanarooj S, Innis B, Nimmannitya S, Suntayakorn S . Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis. 1999; 181(1):2-9. DOI: 10.1086/315215. View

Stack A, Malley R, Saladino R, Montana J, MacDonald K, Molrine D . Primary respiratory syncytial virus infection: pathology, immune response, and evaluation of vaccine challenge strains in a new mouse model. Vaccine. 2000; 18(14):1412-8. DOI: 10.1016/s0264-410x(99)00399-0. View

Bankamp B, Kearney S, Liu X, Bellini W, Rota P . Activity of polymerase proteins of vaccine and wild-type measles virus strains in a minigenome replication assay. J Virol. 2002; 76(14):7073-81. PMC: 136314. DOI: 10.1128/jvi.76.14.7073-7081.2002. View

10.

Poutanen S, Low D, Henry B, Finkelstein S, Rose D, Green K . Identification of severe acute respiratory syndrome in Canada. N Engl J Med. 2003; 348(20):1995-2005. DOI: 10.1056/NEJMoa030634. View

11.

Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt G . A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003; 348(20):1986-94. DOI: 10.1056/NEJMoa030685. View

12.

Drosten C, Gunther S, Preiser W, van der Werf S, Brodt H, Becker S . Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003; 348(20):1967-76. DOI: 10.1056/NEJMoa030747. View

13.

Ksiazek T, Erdman D, Goldsmith C, Zaki S, Peret T, Emery S . A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003; 348(20):1953-66. DOI: 10.1056/NEJMoa030781. View

14.

Fouchier R, Kuiken T, Schutten M, van Amerongen G, van Doornum G, van den Hoogen B . Aetiology: Koch's postulates fulfilled for SARS virus. Nature. 2003; 423(6937):240. PMC: 7095368. DOI: 10.1038/423240a. View

15.

Holmes K . SARS coronavirus: a new challenge for prevention and therapy. J Clin Invest. 2003; 111(11):1605-9. PMC: 156116. DOI: 10.1172/JCI18819. View

16.

Donnelly C, Ghani A, Leung G, Hedley A, Fraser C, Riley S . Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. Lancet. 2003; 361(9371):1761-6. PMC: 7112380. DOI: 10.1016/S0140-6736(03)13410-1. View

17.

Peiris J, Chu C, Cheng V, Chan K, Hung I, Poon L . Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003; 361(9371):1767-72. PMC: 7112410. DOI: 10.1016/s0140-6736(03)13412-5. View

18.

Booth C, Matukas L, Tomlinson G, Rachlis A, Rose D, Dwosh H . Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003; 289(21):2801-9. DOI: 10.1001/jama.289.21.JOC30885. View

19.

Fowler R, Lapinsky S, Hallett D, Detsky A, Sibbald W, Slutsky A . Critically ill patients with severe acute respiratory syndrome. JAMA. 2003; 290(3):367-73. DOI: 10.1001/jama.290.3.367. View

20.

Lew T, Kwek T, Tai D, Earnest A, Loo S, Singh K . Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. JAMA. 2003; 290(3):374-80. DOI: 10.1001/jama.290.3.374. View